Loading
Tumor / Tumor Microenvironment / Drug Resistance, Neoplasm · Journal article
Drug Delivery · May 27, 2026
A consensus or society position rather than new primary data.
This is a narrative review synthesizing the mechanistic basis, design principles, and therapeutic rationale for lysosome-targeting chimeras (LYTACs) as an emerging strategy to overcome cancer drug resistance. The article characterizes LYTACs as a paradigm-shifting approach still in early development stages, with translational bottlenecks in delivery efficiency, receptor heterogeneity, and pharmacokinetics not yet resolved in clinical trials.
Journal article. Patients with cancer, with emphasis on those with drug-resistant disease across chemotherapy, targeted therapy, and immunotherapy contexts; no specific clinical trial population..
Approximately 30% of patients with ER-positive, HER2-negative breast cancer develop resistance to endocrine therapy within 5 years LYTACs extend targeted protein degradation to extracellular and membrane-associated proteins beyond the reach of PROTACs by engaging lysosomal trafficking receptors LYTACs can degrade resistance-associated drivers including efflux pumps (ABCG2), receptor tyrosine kinases (EGFR, MET), immune checkpoint ligands (PD-L1), and extracellular matrix proteins
No primary experimental data, clinical trial results, or efficacy/safety endpoints reported. No quantitative comparison of LYTAC versus PROTAC degradation efficiency, stability, or in vivo pharmacokinetics provided.
Clinicians should understand LYTACs as a conceptually promising but preclinically and early-translationally staged technology not yet validated in clinical trials. The therapeutic strategy may eventually address resistance mechanisms intractable to conventional inhibitors, but current translational barriers must be resolved before clinical application is feasible.
A comprehensive review article synthesizing mechanistic principles and design strategies for an emerging therapeutic modality (LYTACs) in preclinical and early translational stages, with no primary experimental data or clinical trial results.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians should understand LYTACs as a conceptually promising but preclinically and early-translationally staged technology not yet validated in clinical trials. The therapeutic strategy may eventually address resistance mechanisms intractable to conventional inhibitors, but current translational barriers must be resolved before clinical application is feasible.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Targeted protein degradation (TPD) has emerged as a promising therapeutic strategy to address cancer drug resistance by enabling the selective and efficient degradation of disease-associated proteins through cellular mechanisms. Since 2020, lysosome-targeting chimeras (LYTACs) have gained attention for expanding targeted protein degradation to extracellular and membrane-associated disease-related proteins beyond the reach of proteolysis-targeting chimeras (PROTACs). In practice, LYTACs can overcome resistance by degrading instead of inhibiting them. This efficient and durable removal of resistance-associated drivers thereby suppresses compensatory signaling, restores drug sensitivity, and contributes to remodeling the tumor microenvironment. To facilitate the clinical translation of this emerging technology, this review systematically compares the mechanistic and functional advantages of LYTACs over PROTACs, summarizes key design principles, and categorizes major LYTAC modalities, including AbTACs, MoDE-As, and nano-LYTACs. We further discuss their in vivo pharmacological behaviors, with particular emphasis on stability, tumor selectivity, and degradation efficiency. Importantly, this article comprehensively highlights recent advances in the application of LYTACs for overcoming therapeutic resistance, including resistance to chemotherapy, targeted therapy, and immunotherapy. Finally, current translational bottlenecks, such as delivery efficiency, receptor heterogeneity, and pharmacokinetic limitations, are critically analyzed. Collectively, while still in its early stages of development, LYTAC-based lysosomal degradation represents a promising, paradigm-shifting strategy for targeting previously intractable mechanisms of cancer resistance.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.